

Brief information about the project

Name of the project	AP19675905 «Study of immunogenetic and clinical predictors of immunopathology: infectious and autoimmune diseases after SARSCov2 infection»
Relevance	The project opens up opportunities for developing criteria for the rapid progression of damage to organs and systems in post-COVID19 syndromes (MCTD, vasculitis, hepatitis, etc.) for choosing treatment tactics and preventing complications and adverse patient outcomes based on the analysis of the data obtained.
Purpose	The goal of the project is to study immunogenetics, immunological parameters, clinical features of the course of immunopathology (infectious, autoimmune, lymphoproliferative) in patients in the long-term period after SARSCov-2 infection. The choice of the research topic is due to the increase in the number of patients with severe infectious and autoimmune pathology after suffering SARSCov-2. This fact may be due to the fact that in patients with severe immunopathology in post-COVID19, the adaptive immune response cannot sufficiently ensure the elimination of the virus, which causes the persistence of the virus and/or its antigens.
Objectives	<ol style="list-style-type: none"> 1) To study the process of restoring the function of the immune system (CD-profile and functional peripheral blood lymphocytes) of patients who underwent COVID19 in the dynamics of the infectious process in the period from several months to two years. 2) To study the options for the development of SARSCov-2 associated immunopathology in connection with the nature and severity of disorders in immunoregulation in the post-COVID19 period (disturbance in the process of restoring the functions of the immune system during the period of COVID19 convalescence) 3) To study the clinical variants of SARSCov-2 associated immunopathology (multisystem inflammatory syndrome, systemic SARSCov-2-associated vasculitis and DLST-like syndromes, reactivation of chronic persistent infections), their difference from the typical course in other diseases and conditions 4) Describe the clinical and immunological features of post-COVID19 in humans, options for the development of immunopathological events, including fatal ones with the development of risk factors for adverse events - genetic, immunological, clinical. 5) To develop prognostic immunogenetic and immunological criteria for the rapid progression of damage to organs and systems in post-COVID19 syndromes (DBST, vasculitis, hepatitis, etc.) to select treatment tactics and prevent complications and adverse patient outcomes based on the analysis of the data obtained.
Expected and achieved results	<ol style="list-style-type: none"> 1. A registration card for clinical data and immunological parameters will be developed. 2. An analytical review will be conducted on the immune response and 2023 immunopathological changes in COVID19. 3. Work will be carried out to conduct a clinical examination and analysis of medical documentation of patients in the hospital, randomization and selection of patients for an in-depth examination according to inclusion and exclusion criteria.

	<p>4. Data on a scientific topic will be presented in at least 2 international congresses and at least 2 domestic conferences.</p> <p>5. Over the entire period of project implementation, articles in rating journals will be prepared and published in accordance with the requirements of the competition documentation:</p> <ul style="list-style-type: none"> - at least 3 (three) articles and (or) reviews in peer-reviewed scientific publications indexed in the Science Citation Index Expanded of the Web of Science database and (or) having a CiteScore percentile in the Scopus database of at least 35 (thirty-five); - as well as at least 1 (one) article or review in a peer-reviewed foreign or domestic publication recommended by KOKSNVO; - or at least 2 (two) peer-reviewed articles and (or) reviews scientific publications indexed in the Science Citation Index Expanded and included in the 1st (first) and (or) 2nd (second) quartile by impact factor in the Web of Science database and (or) having a percentile according to Cite Score in the Scopus database of at least 65 (sixty five); - or at least 1 (one) article or review of a peer-reviewed scientific publication indexed in the Science Citation Index Expanded and included in the 1 (first) quartile by impact factor in the Web of Science database and (or) having a CiteScore percentile in the Scopus database of at least 80 (eighty).
<p>Research team members with their identifiers (Scopus Author ID, Researcher ID, ORCID, if available) and links to relevant profiles</p>	<ol style="list-style-type: none"> 1. Trimova Gulzhan Shakrafovna, PhD, Hirsch index – 5, Researcher ID, ORCID: 0000-0001-8130-4150, Scopus author ID: 56556992400 2. Kurmanova Gaukhar Medeubaevna, Doctor of Medical Sciences, Professor, Hirsch Index – 2; ORCID: 0000-0002-5768-0209, Scopus Author ID: 6507474504. 3. Kulembaeva Anarkul Bakirovna, Ph.D. 4. Idrisova Gulzhan Maksutovna 5. Beisebaeva Aliya Kairatovna 6. Rakhimbaeva Madina Sakenovna
<p>List of publications with links to them</p>	<p>“Comparative characteristics of the course Of covid-19 in the city of Almaty in 2020-2021” A.M. Kurmanova, A.E. Karimsakova, G.M. Kurmanova, G.Sh. Trimova DOI 10.53511/PHARMKAZ.2024.11.87.007</p>
<p>Patents</p>	<p>-</p>

